Drug Trial Radar · NCT03104595
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Oct 30, 2017
Primary completion
Nov 26, 2019
Study completion Dec 5, 2019
Sponsor
- Lead sponsor
- Enzychem Lifesciences CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.
Conditions
- Febrile Neutropenia
Interventions
EC-18Drug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Duration of Grade 4 NeutropeniaTime frame: During Cycle 1 of chemotherapy (up to 21 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center
Gyeonggi-do, Gyeonggi-do, South Korea
Yonsei University Health System Severance Hospital
Seoul, Seoul, South Korea
Asan Medical Center
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.